Replacement of reduced highly unsaturated fatty acids (HUFA deficiency) in dilative heart failure: Dosage of EPA/DHA and variability of adverse peroxides and aldehydes in dietary supplement fish oils

Cardiology (Switzerland)

Volumn 125, Issue 4, 2013, Pages 223-231

  Rupp, Thomas P ^a   Rupp, Karin G ^a   Alter, Peter ^a   Rupp, Heinz ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

3 fatty acids; Aldehydes; DHA; Dilative heart failure; EPA; Fish oil; Oxidation products; Peroxides

Indexed keywords

ALDEHYDE; ALKENE DERIVATIVE; DOCOSAHEXAENOIC ACID; FISH OIL; ICOSAPENTAENOIC ACID; OMEGA 3 ACID ETHYL ESTER; PEROXIDE; UNSATURATED FATTY ACID; HIGHLY UNSATURATED FATTY ACID; OMEGA 3 FATTY ACID; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIET SUPPLEMENTATION; ESSENTIAL FATTY ACID DEFICIENCY; FATTY ACID OXIDATION; FEMALE; FOOD AND DRUG ADMINISTRATION; FOOD INTAKE; GAS CHROMATOGRAPHY; HEART DILATATION; HEART FAILURE; HEART FUNCTION; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HIGHLY UNSATURATED FATTY ACID DEFICIENCY; HUMAN; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; PHOTOMETRY; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; DILATIVE HEART FAILURE; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME;

ALDEHYDES; CARDIOMYOPATHY, DILATED; CARDIOTONIC AGENTS; DIETARY SUPPLEMENTS; DOCOSAHEXAENOIC ACIDS; EICOSAPENTAENOIC ACID; FATTY ACIDS, UNSATURATED; FISH OILS; HEART FAILURE; HUMANS; HYPERTRIGLYCERIDEMIA; MYOCARDIAL INFARCTION; OXIDANTS; PEROXIDES; ROC CURVE; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84879465339     PISSN: 00086312     EISSN: 14219751     Source Type: Journal    
DOI: 10.1159/000350656     Document Type: Article

References (50)

1. Krum H, Teerlink JR: Medical therapy for chronic heart failure. Lancet 2011; 378: 713-721.
2. Turcani M, Rupp H: Etomoxir improves left ventricular performance of pressure-overloaded rat heart. Circulation 1997; 96: 3681-3686. (Pubitemid 27513449)
3. Holubarsch CJ, Rohrbach M, Karrasch M, Boehm E, Polonski L, Ponikowski P, Rhein S: A double-blind randomized multicentre clinical trial to evaluate the efficacy and safety of two doses of etomoxir in comparison with placebo in patients with moderate congestive heart failure: the ERGO (etomoxir for the recovery of glucose oxidation) study. Clin Sci (Lond) 2007; 113: 205-212. (Pubitemid 47237917)
4. Rupp H, Rupp TP, Alter P, Maisch B: Acute heart failure - basic pathomechanism and new drug targets. Herz 2006; 31: 727-735. (Pubitemid 44934645)
5. Rupp H, Rupp TP, Wagner D, Alter P, Maisch B: Microdetermination of fatty acids by gas chromatography and cardiovascular risk stratification by the 'EPA+DHA level'. Herz 2006; 31(suppl 3):30-49.
6. Alter P, Rupp H, Adams P, Stoll F, Figiel JH, Klose KJ, Rominger MB, Maisch B: Occurrence of late gadolinium enhancement is associated with increased left ventricular wall stress and mass in patients with non-ischaemic dilated cardiomyopathy. Eur J Heart Fail 2011; 13: 937-944.
7. Alter P, Rupp H, Stoll F, Adams P, Figiel JH, Klose KJ, Rominger MB, Maisch B: Increased end diastolic wall stress precedes left ventricular hypertrophy in dilative heart failure - use of the volume-based wall stress index. Int J Cardiol 2012; 157: 233-238.
8. Alter P, Apelt S, Figiel JH, Rominger MB, Rupp H, Heitmann J: The missing link between heart failure and sleep disordered breathing: increased left ventricular wall stress. Int J Cardiol 2012; 157: 294-297.
9. GISSI-Prevenzione Investigators: Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet 1999; 354: 447-455.
10. Macchia A, Levantesi G, Franzosi MG, Geraci E, Maggioni AP, Marfisi R, Nicolosi GL, Schweiger C, Tavazzi L, Tognoni G, Valagussa F, Marchioli R: Left ventricular systolic dysfunction, total mortality, and sudden death in patients with myocardial infarction treated with n-3 polyunsaturated fatty acids. Eur J Heart Fail 2005; 7: 904-909. (Pubitemid 41125915)
11. Rupp H, Rupp TP, Alter P, Maisch B: N-3 polyunsaturated fatty acids and statins in heart failure. Lancet 2009; 373: 378-379.
12. Rupp H, Rupp TP, Alter P, Maisch B: Inverse shift in serum polyunsaturated and monounsaturated fatty acids is associated with adverse dilatation of the heart. Heart 2010; 96: 595-598.
13. Rupp H, Rupp TP, Alter P, Maisch B: Mechanisms involved in the differential reduction of omega-3 and omega-6 highly unsaturated fatty acids by structural heart disease resulting in 'HUFA deficiency'. Can J Physiol Pharmacol 2012; 90: 55-73.
14. Xiao YF, Sigg DC, Leaf A: The antiarrhythmic effect of n-3 polyunsaturated fatty acids: modulation of cardiac ion channels as a potential mechanism. J Membr Biol 2005; 206: 141- 154. (Pubitemid 43199147)
15. Ohkubo T, Jacob R, Rupp H: Swimming changes vascular fatty acid composition and prostanoidgeneration of rats. Am J Physiol 1992; 262:R464-R471.
16. Rupp H: Omacor (prescription omega-3-acid ethyl esters 90): from severe rhythm disorders to hypertriglyceridemia. Adv Ther 2009; 26: 675-690.
17. Halvorsen BL, Blomhoff R: Determinationof lipid oxidation products in vegetable oils and marine omega-3 supplements. Food Nutr Res 2011; 55:DOI: 10.3402/fnr.v55i0.5792.
18. GISSI-HF Investigators: Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008; 372: 1223-1230.
19. Poole CD, Halcox JP, Jenkins-Jones S, Carr ES, Schifflers MG, Ray KK, Currie CJ: Omega-3 fatty acids and mortality outcome in patients with and without type 2 diabetes after myocardial infarction: a retrospective, matched-cohort study. Clin Ther 2013; 35: 40-51.
20. Mozaffarian D, Wu JH: (n-3) fatty acids and cardiovascular health: are effects of EPA and DHA shared or complementary? J Nutr 2012; 142: 614S-625S.
21. Die nationale Verzehrsstudie. Bremerhaven, Wirtschaftsverlag NW, 1991.
22. Marchioli R, Barzi F, Bomba E, Chieffo C, Di Gregorio D, Di Mascio R, Franzosi MG, Geraci E, Levantesi G, Maggioni AP, Mantini L, Marfisi RM, Mastrogiuseppe G, Mininni N, Nicolosi GL, Santini M, Schweiger C, Tavazzi L, Tognoni G, Tucci C, Valagussa F: Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction:time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-Prevenzione. Circulation 2002; 105: 1897-1903. (Pubitemid 34437615)
23. Marchioli R, Franzosi MG, Latini R, Maggioni AP, Marfisi RM, Nicolosi GL, Picchio E, Porcu M, Severini D, Tavazzi L: Effect of n-3 PUFA in heart failure patients with different dietary habits: preliminary results of the GISSI- Heart Failure trial. Eur Heart J 2009; 30(suppl):426.
24. Rupp H, Wagner D, Rupp T, Schulte LM, Maisch B: Risk stratification by the 'EPA+ DHA level' and the 'EPA/AA ratio' focus on anti-inflammatory and antiarrhythmogenic effects of long-chain omega-3 fatty acids. Herz 2004; 29: 673-685. (Pubitemid 40064639)
25. Dijkstra SC, Brouwer IA, van Rooij FJ, Hofman A, Witteman JC, Geleijnse JM: Intake of very long chain n-3 fatty acids from fish and the incidence of heart failure: the Rotterdam Study. Eur J Heart Fail 2009; 11: 922-928.
26. Ghio S, Scelsi L, Latini R, Masson S, Eleuteri E, Palvarini M, Vriz O, Pasotti M, Gorini M, Marchioli R, Maggioni A, Tavazzi L: Effects of n-3 polyunsaturated fatty acids and of rosuvastatin on left ventricular function in chronic heart failure: a substudy of GISSI-HF trial. Eur J Heart Fail 2010; 12: 1345-1353.
27. Bosch J, Gerstein HC, Dagenais GR, Diaz R, Dyal L, Jung H, Maggiono AP, Probstfield J, Ramachandran A, Riddle MC, Ryden LE, Yusuf S: n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med 2012; 367: 309-318.
28. Rauch B, Schiele R, Schneider S, Diller F, Victor N, Gohlke H, Gottwik M, Steinbeck G, Del Castillo U, Sack R, Worth H, Katus H, Spitzer W, Sabin G, Senges J: OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction. Circulation 2010; 122: 2152-2159.
29. Alter P, Rupp H: Letter by Alter and Rupp regarding article, 'OMEGA, a randomized, placebo- controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction'. Circulation 2011; 124:e23.
30. Moertl D, Hammer A, Steiner S, Hutuleac R, Vonbank K, Berger R: Dose-dependent effects of omega-3-polyunsaturated fatty acids on systolic left ventricular function, endothelial function, and markers of inflammation in chronic heart failure of nonischemic origin: a doubleblind, placebo-controlled, 3-arm study. Am Heart J 2011; 161: 915-919.
31. Nodari S, Triggiani M, Campia U, Manerba A, Milesi G, Cesana BM, Gheorghiade M, Dei Cas L: Effects of n-3 polyunsaturated fatty acids on left ventricular function and functional capacity in patients with dilated cardiomyopathy. J Am Coll Cardiol 2011; 57: 870-879.
32. Rupp H, Rupp TP, Alter P, Maisch B: Failure of omega-3 fatty acids in atrial fibrillation? No deficiency of highly unsaturated fatty acids in the absence of heart failure. Europace 2011; 13: 1357-1358.
33. Gerster H: Can adults adequately convert alphalinolenic acid (18: 3n-3) to eicosapentaenoic acid (20: 5n-3) and docosahexaenoic acid (22: 6n-3)? Int J Vitam Nutr Res 1998; 68: 159-173. (Pubitemid 28259765)
34. Ander BP, Edel AL, McCullough R, Rodriguez- Leyva D, Rampersad P, Gilchrist JS, Lukas A, Pierce GN: Distribution of omega-3 fatty acids in tissues of rabbits fed a flaxseed-supplemented diet. Metabolism 2010; 59: 620-627.
35. Rodriguez-Leyva D, Dupasquier CM, Mc- Cullough R, Pierce GN: The cardiovascular effects of flaxseed and its omega-3 fatty acid, alpha-linolenic acid. Can J Cardiol 2010; 26: 489-496.
36. Leyva DR, Zahradka P, Ramjiawan B, Guzman R, Aliani M, Pierce GN: The effect of dietary flaxseed on improving symptoms of cardiovascular disease in patients with peripheral artery disease: rationale and design of the FLAX-PAD randomized controlled trial. Contemp Clin Trials 2011; 32: 724-730.
37. Mendez L, Pazos M, Gallardo JM, Torres JL, Perez-Jimenez J, Nogues R, Romeu M, Medina I: Reduced protein oxidation in Wistar rats supplemented with marine omega-3 PUFAs. Free Radic Biol Med 2012; 55C:8-20.
38. Karahadian C, Lindsay RC: Evaluation of compounds contributing characterizing fishy flavors in fish oils. J Am Oil Chem Soc 1989; 66: 953-960.
39. EFSA Panel on Biological Hazards (BIOHAZ): Scientific opinion on fish oil for human consumption. Food hygiene, including rancidity. EFSA J 2010; 8: 1874-1922.
40. Osawa CC, Goncalves LAG, Ragazzi S: Determination of hydroperoxides in oils and fats using kits. J Sci Food Agric 2007; 87: 1659-1666. (Pubitemid 46983819)
41. Ruyter B, Grimmer S, Thorkildsen T, Todorcevic M, Lalic M: Lite oksiderte omega-3 oljer og potensielle helsefordeler. Trondheim, Rubin 2010;196:1-60.
42. European Pharmacopoeia. Strasbourg, Directorate for the Quality of Medicines and Health- Care of the Council of Europe, 2012.
43. Opperman M, Marais de W, Spinnler Benade AJ: Analysis of omega-3 fatty acid content of South African fish oil supplements. Cardiovasc J Afr 2011; 22: 324-329.
44. Osawa CC, Goncalves LAG, Ragazzi S: The use of fast methodologies (kits) in evaluating deep-frying oils. J Am Oil Chem Soc 2007; 84: 893-897. (Pubitemid 47482103)
45. Aursand M, Mozuraityte R, Hamre K, Knutsen H, Maage A, Arukwe A: Description of the Processes in the Value Chain and Risk Assessment of Decomposition Substances and Oxidation Products in Fish Oils. Oslo, Norwegian Scientific Committee for Food Safety (VKM), 2011.
46. Wilson R, Lyall K, Millar EM, Smyth L, Pearson C, Riemersma RA: Do oxidized fatty acids activate coagulation factor VII during postprandial lipemia in women? Thromb Haemost 2003; 89: 654-659. (Pubitemid 36456962)
47. Turner R, McLean CH, Silvers KM: Are the health benefits of fish oils limited by products of oxidation? Nutr Res Rev 2006; 19: 53-62. (Pubitemid 44174293)
48. Krum H, Jelinek MV, Stewart S, Sindone A, Atherton JJ, National Heart Foundation of Australia, Cardiac Society of Australia and New Zealand: 2011 update to National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand Guidelines for the prevention, detection and management of chronic heart failure in Australia, 2006. Med J Aust 2011; 194: 405-409.
49. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Kober L, Lip GY, Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Ronnevik PK, Rutten FH, Schwitter J, Seferovic P, Stepinska J, Trindade PT, Voors AA, Zannad F, Zeiher A: ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012; 33: 1787-1847.
50. Collins N, Tighe AP, Brunton SA, Kris-Etherton PM: Differences between dietary supplement and prescription drug omega-3 fatty acid formulations: a legislative and regulatory perspective. J Am Coll Nutr 2008; 27: 659-666.